Foresight Acquisition: Recent buzz on X about Natera, Inc. (NTRA) centers on its acquisition of Foresight Diagnostics for $275 million upfront, with potential earnouts of $175 million. Many users are discussing how this move could strengthen Natera's position in early cancer detection. The deal has sparked curiosity about future growth in precision medicine.
Signatera Data and Share Offering: Discussions also highlight Natera's upcoming Signatera test data presentation at the 2025 ASH Annual Meeting, with some on X noting its potential to outperform imaging in lymphoma detection. Additionally, the recent filing for a share offering worth nearly $479 million has raised questions about dilution and funding strategy. Users are split on the long-term impact of these developments.
Note: This discussion summary was generated from an AI condensation of post data.
Natera, Inc. Insider Trading Activity
Natera, Inc. insiders have traded $NTRA stock on the open market 201 times in the past 6 months. Of those trades, 0 have been purchases and 201 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 25 sales selling 219,856 shares for an estimated $41,950,665.
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 12 sales selling 111,718 shares for an estimated $20,850,493.
- ROELOF BOTHA has made 0 purchases and 11 sales selling 75,000 shares for an estimated $17,708,935.
- JONATHAN SHEENA has made 0 purchases and 71 sales selling 60,564 shares for an estimated $11,290,945.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 9 sales selling 26,187 shares for an estimated $4,428,423.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 27 sales selling 23,870 shares for an estimated $4,152,157.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 23 sales selling 18,162 shares for an estimated $2,985,740.
- ROY D. BAYNES has made 0 purchases and 8 sales selling 12,780 shares for an estimated $2,809,688.
- GAIL BOXER MARCUS has made 0 purchases and 7 sales selling 10,917 shares for an estimated $1,733,888.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 7 sales selling 4,775 shares for an estimated $783,289.
- ROWAN E CHAPMAN sold 2,750 shares for an estimated $459,222
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Natera, Inc. Revenue
Natera, Inc. had revenues of $592.2M in Q3 2025. This is an increase of 34.66% from the same period in the prior year.
You can track NTRA financials on Quiver Quantitative's NTRA stock page.
Natera, Inc. Congressional Stock Trading
Members of Congress have traded $NTRA stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 3 times. They made 2 purchases worth up to $30,000 on 09/22, 08/22 and 1 sale worth up to $15,000 on 07/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Natera, Inc. Hedge Fund Activity
We have seen 384 institutional investors add shares of Natera, Inc. stock to their portfolio, and 327 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KYNAM CAPITAL MANAGEMENT, LP removed 1,167,570 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $197,249,275
- JPMORGAN CHASE & CO added 1,003,129 shares (+9.4%) to their portfolio in Q3 2025, for an estimated $161,473,675
- POINTSTATE CAPITAL LP added 985,963 shares (+702.0%) to their portfolio in Q3 2025, for an estimated $158,710,464
- FRANKLIN RESOURCES INC added 727,366 shares (+37.5%) to their portfolio in Q3 2025, for an estimated $117,084,105
- AQR CAPITAL MANAGEMENT LLC added 673,315 shares (+39.0%) to their portfolio in Q3 2025, for an estimated $108,383,515
- INVESCO LTD. removed 649,956 shares (-34.7%) from their portfolio in Q3 2025, for an estimated $104,623,417
- AMERIPRISE FINANCIAL INC removed 626,686 shares (-67.0%) from their portfolio in Q3 2025, for an estimated $100,877,645
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Natera, Inc. Government Contracts
We have seen $296,845 of award payments to $NTRA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- MODIFICATION TO EXTEND THE POP FOR SIX (6) MONTHS: $140,595
- GENETIC TESTING: $79,200
- TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $77,050
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Natera, Inc. Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 12/05/2025
- JP Morgan issued a "Overweight" rating on 11/25/2025
- UBS issued a "Buy" rating on 11/18/2025
- Stephens & Co. issued a "Overweight" rating on 11/13/2025
- Piper Sandler issued a "Overweight" rating on 11/11/2025
- Morgan Stanley issued a "Overweight" rating on 11/11/2025
- Barclays issued a "Overweight" rating on 11/07/2025
To track analyst ratings and price targets for Natera, Inc., check out Quiver Quantitative's $NTRA forecast page.
Natera, Inc. Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 11 analysts offer price targets for $NTRA in the last 6 months, with a median target of $250.0.
Here are some recent targets:
- Mark Massaro from BTIG set a target price of $260.0 on 12/05/2025
- Tejas Savant from Morgan Stanley set a target price of $265.0 on 12/02/2025
- Casey Woodring from JP Morgan set a target price of $250.0 on 11/25/2025
- Elizabeth Garcia from UBS set a target price of $280.0 on 11/18/2025
- Mason Carrico from Stephens & Co. set a target price of $235.0 on 11/13/2025
- David Westenberg from Piper Sandler set a target price of $230.0 on 11/11/2025
- Kyle Mikson from Canaccord Genuity set a target price of $250.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
